BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chakraborty E, Sarkar D. Emerging Therapies for Hepatocellular Carcinoma (HCC). Cancers (Basel) 2022;14. [PMID: 35681776 DOI: 10.3390/cancers14112798] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 28.0] [Reference Citation Analysis]
Number Citing Articles
1 Cui Q, Wang X, Zhang Y, Shen Y, Qian Y. Macrophage-Derived MMP-9 and MMP-2 are Closely Related to the Rupture of the Fibrous Capsule of Hepatocellular Carcinoma Leading to Tumor Invasion. Biol Proced Online 2023;25:8. [PMID: 36918768 DOI: 10.1186/s12575-023-00196-0] [Reference Citation Analysis]
2 Huang P, Wang L, Wang Y, Tsai M, Lin T, Liao C, Yeh C, Lin K. Evaluation and Application of Drug Resistance by Biomarkers in the Clinical Treatment of Liver Cancer. Cells 2023;12:869. [DOI: 10.3390/cells12060869] [Reference Citation Analysis]
3 Nephew LD, Gupta D, Carter A, Desai AP, Ghabril M, Patidar KR, Orman E, Dziarski A, Chalasani N. Social determinants of health impact mortality from HCC and cholangiocarcinoma: a population-based cohort study. Hepatol Commun 2023;7:e0058. [PMID: 36757397 DOI: 10.1097/HC9.0000000000000058] [Reference Citation Analysis]
4 Minaei N, Ramezankhani R, Tamimi A, Piryaei A, Zarrabi A, Aref AR, Mostafavi E, Vosough M. Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future. Eur J Cell Biol 2023;102:151284. [PMID: 36584598 DOI: 10.1016/j.ejcb.2022.151284] [Reference Citation Analysis]
5 Gao Q, Sun Z, Fang D. Integrins in human hepatocellular carcinoma tumorigenesis and therapy. Chin Med J (Engl) 2023. [PMID: 36848180 DOI: 10.1097/CM9.0000000000002459] [Reference Citation Analysis]
6 Peng Q, Li J, Wu Q, Wang P, Kang Z, Deng Y, Xiao Y, Zheng P, Ge F, Chen Y. ZNF385A and ZNF346 Serve as Prognostic Biomarkers Associated with an Inflamed Immunosuppressive Tumor Microenvironment in Hepatocellular Carcinoma. Int J Mol Sci 2023;24. [PMID: 36834567 DOI: 10.3390/ijms24043155] [Reference Citation Analysis]
7 Toro AU, Kurya AU, Shukla SK, Bansal P. Emerging Role of MicroRNA-Based Theranostics in Advanced Hepatocellular Carcinoma.. [DOI: 10.21203/rs.3.rs-2505882/v1] [Reference Citation Analysis]
8 Saber S, El-Fattah EEA, Abdelhamid AM, Mourad AAE, Hamouda MAM, Elrabat A, Zakaria S, Haleem AA, Mohamed SZ, Elgharabawy RM, Morsy NE, El Adle Khalaf N, Mohammed OA, El-Bahouty WB, Mostafa SA, Abdelhady R, Galal O, ElSaid ZH, Yahya G, Shata A, Youssef ME. Innovative challenge for the inhibition of hepatocellular carcinoma progression by combined targeting of HSP90 and STAT3/HIF-1α signaling. Biomed Pharmacother 2023;158:114196. [PMID: 36916405 DOI: 10.1016/j.biopha.2022.114196] [Reference Citation Analysis]
9 Zheng Z, Ma M, Han X, Li X, Huang J, Zhao Y, Liu H, Kang J, Kong X, Sun G, Sun G, Kong J, Tang W, Shao G, Xiong F, Song J. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma. Acta Biomater 2023;157:337-51. [PMID: 36509402 DOI: 10.1016/j.actbio.2022.12.004] [Reference Citation Analysis]
10 Hwangbo H, Kim DH, Kim MY, Ji SY, Bang E, Hong SH, Choi YH, Cheong J. Auranofin accelerates spermidine-induced apoptosis via reactive oxygen species generation and suppression of PI3K/Akt signaling pathway in hepatocellular carcinoma. Fish Aquat Sci 2023;26:133-144. [DOI: 10.47853/fas.2023.e11] [Reference Citation Analysis]
11 Wei Y, Ke W, Lu Z, Ren Y. PI3K δ inhibitor PI-3065 induces apoptosis in hepatocellular carcinoma cells by targeting survivin. Chem Biol Interact 2023;371:110343. [PMID: 36623716 DOI: 10.1016/j.cbi.2023.110343] [Reference Citation Analysis]
12 Zhang H, Chen Z, Zhao X, Huo Q, Cheng X. [Shikonin induces hepatocellular carcinoma cell apoptosis by suppressing PKM2/PHD3/HIF-1α signaling pathway]. Nan Fang Yi Ke Da Xue Xue Bao 2023;43:92-8. [PMID: 36856215 DOI: 10.12122/j.issn.1673-4254.2023.01.12] [Reference Citation Analysis]
13 Qiu X, Xu H, Wang K, Gao F, Xu X, He H. P-21 Activated Kinases in Liver Disorders. Cancers (Basel) 2023;15. [PMID: 36672500 DOI: 10.3390/cancers15020551] [Reference Citation Analysis]
14 Huang Y, Wang S, Ke A, Guo K. Ferroptosis and its interaction with tumor immune microenvironment in liver cancer. Biochim Biophys Acta Rev Cancer 2023;1878:188848. [PMID: 36502929 DOI: 10.1016/j.bbcan.2022.188848] [Reference Citation Analysis]
15 Kuzmanović A, Lin C, Bartneck M. Liver Cancer and the Curative Potential of Nanomedicine. Interdisciplinary Cancer Research 2023. [DOI: 10.1007/16833_2023_129] [Reference Citation Analysis]
16 Li X, Sun X, Wang B, Li Y, Tong J. Oncolytic virus-based hepatocellular carcinoma treatment: Current status, intravenous delivery strategies, and emerging combination therapeutic solutions. Asian J Pharm Sci 2023;18:100771. [PMID: 36896445 DOI: 10.1016/j.ajps.2022.100771] [Reference Citation Analysis]
17 Zhao Y, Zhang L, Hu Q, Zhu D, Xie Z. Identification and analysis of C17orf53 as a prognostic signature for hepatocellular carcinoma. Comput Biol Med 2023;152:106348. [PMID: 36470143 DOI: 10.1016/j.compbiomed.2022.106348] [Reference Citation Analysis]
18 Wang H, Chen W, Qi Y, Liu D, Liu Z, Zhang Q, Yi Y, Wang J, Wu W. miR-29c Suppresses the Malignant Phenotype of Hepatocellular Carcinoma Cells In Vitro by Mediating TPX2 Associated with Immune Infiltration. Dig Dis Sci 2022. [PMID: 36583803 DOI: 10.1007/s10620-022-07810-3] [Reference Citation Analysis]
19 Cui Q, Wang X, Zhang Y, Shen Y, Qian Y. Macrophage-derived MMP-9/MMP-2 are closely related to the rupture of the fibrous capsule of hepatocellular carcinoma leading to tumor invasion.. [DOI: 10.21203/rs.3.rs-2379884/v1] [Reference Citation Analysis]
20 Wei B, Hao Z, Zheng H, Qin Y, Zhao F, Shi L. Brevilin A Inhibits VEGF-Induced Angiogenesis through ROS-Dependent Mitochondrial Dysfunction. Oxid Med Cell Longev 2022;2022:5888636. [PMID: 36567856 DOI: 10.1155/2022/5888636] [Reference Citation Analysis]
21 Rizzo A, Ricci AD, Brandi G. Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update. J Pers Med 2022;12. [PMID: 36579504 DOI: 10.3390/jpm12111788] [Reference Citation Analysis]
22 Ding W, Zhang Z, Ye N, Zhuang L, Yuan Z, Xue W, Tan Y, Xu X, Liu Y. Identification of Key Genes in the HBV-Related HCC Immune Microenvironment Using Integrated Bioinformatics Analysis. Journal of Oncology 2022;2022:1-15. [DOI: 10.1155/2022/2797033] [Reference Citation Analysis]
23 Yu Y, Lu X, Yan Y, Wang Y, Meng J, Tian S, Mu J, Zheng D. The lncRNA KIF9-AS1 Accelerates Hepatocellular Carcinoma Growth by Recruiting DNMT1 to Promote RAI2 DNA Methylation. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/3888798] [Reference Citation Analysis]
24 Wang J, Shen B, Liu X, Jiang J. A novel necroptosis-related lncRNA signature predicts the prognosis and immune microenvironment of hepatocellular carcinoma. Front Genet 2022;13:985191. [DOI: 10.3389/fgene.2022.985191] [Reference Citation Analysis]
25 Sarkar D. Providing meaningful survival benefit to hepatocellular carcinoma patients: combination therapy of future. Hepatobiliary Surg Nutr 2022;11:779-81. [PMID: 36268238 DOI: 10.21037/hbsn-22-322] [Reference Citation Analysis]
26 Deng H, Zhang J, Zheng Y, Li J, Xiao Q, Wei F, Han W, Xu X, Zhang Y. CCDC25 may be a potential diagnostic and prognostic marker of hepatocellular carcinoma: Results from microarray analysis. Front Surg 2022;9. [DOI: 10.3389/fsurg.2022.878648] [Reference Citation Analysis]
27 Caligiuri A, Gitto S, Lori G, Marra F, Parola M, Cannito S, Gentilini A. Oncostatin M: From Intracellular Signaling to Therapeutic Targets in Liver Cancer. Cancers 2022;14:4211. [DOI: 10.3390/cancers14174211] [Reference Citation Analysis]
28 Wu H, Wang M, Zhu J, Li Z, Wang W, Gu L, Shen F, Yang T. Mesoporous Nanoparticles for Diagnosis and Treatment of Liver Cancer in the Era of Precise Medicine. Pharmaceutics 2022;14:1760. [DOI: 10.3390/pharmaceutics14091760] [Reference Citation Analysis]